CG
ALNY icon

Caprock Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Caprock Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,190
Closed -$394K – 1238
2026
Q1 		$394K Buy
1,190
+198
+20% +$67.4K 0.01% 827
2025
Q4 		$394K Buy
992
+135
+16% +$59.7K 0.01% 898
2025
Q3 		$383K Buy
+857
New +$349K 0.01% 868

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caprock Group's ALNY Position: Q2 2026 in Review

Caprock Group sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 1,190 shares — an estimated $394K sold.

Caprock Group first reported a position in ALNY in Q3 2025 and held it in 3 quarters. The position peaked at $394K in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Caprock Group reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Caprock Group sold 1,190 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $394K.
  • Caprock Group first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Caprock Group's Alnylam Pharmaceuticals position peaked at $394K in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.